GNW-Adhoc: ONWARD attends upcoming academic and investor conferences

shares in this article

^EINDHOVEN, Netherlands, LAUSANNE, Switzerland and BOSTON, MA USA, April 12, 2023

(GLOBE NEWSWIRE) — Medical technology company ONWARD Medical NV

(Euronext: ONWD), which offers innovative therapies to restore movement,

Independence and health in people with spinal cord injuries (Spinal

Cord Injury, SCI) announced today that management in the

will attend the following conferences in the coming weeks:

* ASIA 50th Annual Scientific Meeting (https://asia-spinalinjury.org/2023-

annual-scientific-meeting/) (American Spinal Injury Association)

17-19 April 2023

Atlanta, Georgia, United States

Dave Marver, CEO, will be there and attending the conference.

* Needham Annual Healthcare Conference

17-20 April 2023

virtual event

Lara Smith Weber, CFO, will give a company presentation.

* DMGP Congress (https://dmgp-kongress.de/) (36th Annual Meeting of

German-speaking Medical Society for Paraplegiology)

19-22 April

Nottwil, Switzerland

Grégoire Courtine, CSO, together with Dr. Jocelyne Bloch den

give the opening speech.

* LSX World Congress

(https://www.lsxleaders.com/lsx-world-congress)3.-4. May 2023

London, United Kingdom

Dave Marver, CEO, will be present and will participate in a panel discussion

participate.

* “Invest & Connect” by KPMG & the canton’s Chamber of Commerce and Industry

Vaud (CVCI)

June 13, 2023

Lausanne, Switzerland

Lara Smith Weber, CFO, will be speaking at this start-up event

give the opening speech.

* Stifel European Healthcare Conference

28-30 June 2023

Bordeaux, France

Dave Marver, CEO, will be there and attending the conference.

Information on upcoming conferences and events can be found in the

Investors section of the ONWARD website at https://ir.onwd.com/news-events.

About ONWARD Medical

ONWARD is a medical technology company providing innovative therapies for

Restoring movement, independence and health in people with

developed spinal cord injuries. ONWARD’s work is based on more than

a decade of basic research and preclinical development that

performed in the world’s leading neuroscience laboratories. The ARC

Therapy of ONWARD using implantable (ARC-IM) or external (ARC-EX)

Systems can be carried out, serves the purposeful, programmed

Stimulating the spinal cord to control movement and other functions in humans

with spinal cord injuries and other movement disorders.

ONWARD has eight Breakthrough Device Designations from the US FDA

received, which include both ARC-IM and ARC-EX. ARC-EX is an external,

non-invasive platform consisting of a wearable stimulator and a

wireless programmer. 2022 were positive topline results

of the company’s first pivotal study, Up-LIFT, published in the

the ability of ARC-EX Therapy to improve strength and function of the

upper extremities was evaluated. The company is now preparing

submissions for US and European approvals. ARC-IM consists of a

implantable pulse generator and an electrode placed near the

spinal cord is placed. In 2022, the company has the ARC-IM neurostimulator

First human use and positive preliminary clinical results

for ARC-IM therapy for improved blood pressure regulation

published spinal cord injuries.

ONWARD’s headquarters are located in Eindhoven, the Netherlands. The

company has a science and technology center in Lausanne,

Switzerland, and a growing US presence in Boston, Massachusetts. ONWARD

combines an academic partnership with.NeuroRestore, a collaboration

between the Swiss Federal Institute of Technology in Lausanne (EPFL) and the

University Hospital of Lausanne (CHUV). More information about the company

see ONWD.com (https://www.onwd.com/). The 2023 financial calendar

can be found at IR.ONWD.com (https://ir.onwd.com/financial-information).

For corporate inquiries:

[email protected] (mailto:[email protected])

For media inquiries:

MC Services Ltd

USA: Laurie Doyle, P: +1 339 832 0752

Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0

[email protected] (mailto:[email protected])

For investor inquiries:

[email protected] (mailto:[email protected])

Disclaimer

Certain statements, beliefs and opinions contained in this press release are

future-oriented and reflect the current expectations and forecasts of the

company or the board of directors of the company in relation to future

events reflected. It’s in the nature of things to be forward-looking

Statements involve a number of risks, uncertainties and assumptions that

could cause the actual results or events to be material

differ from those expressed in the forward-looking statements or

be implied. These risks, uncertainties and assumptions could

Earnings and the financial impact of the plans described herein and

affect events negatively. A variety of factors including,

but not limited to, changes in demand, competition and

Technology can cause actual events, achievements

or results deviate significantly from anticipated developments.

Forward-looking statements in this press release relate to past

trends or activities are not to be construed as a representation that

these trends or activities will continue in the future. Therefore rejects that

Company expressly disclaims any obligation to provide updates or

Revisions to the forward-looking statements contained in this press release

release statements if expectations or events,

Conditions, assumptions or circumstances on which these forward-looking statements are based

Statements are based, change. Neither the company nor its advisers or

representatives, nor any of its subsidiaries, nor the officers

or employees of these persons guarantee that the assumptions made such

underlying forward-looking statements are accurate

they are responsible for the future accuracy of the information contained in this

Press release contained forward-looking statements or actual

Occurrence of the forecast developments. You shouldn’t get in

undue reliance on forward-looking statements, since they are only

as of the date of this press release.

°